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Abstract
Background: Tenofovir has been associated with renal phosphate wasting, reduced bone mineral density, and higher
parathyroid hormone levels. The aim of this study was to carry out a detailed comparison of the effects of tenofovir versus
non-tenofovir use on calcium, phosphate and, vitamin D, parathyroid hormone (PTH), and bone mineral density.
Methods: A cohort study of 56 HIV-1 infected adults at a single centre in the UK on stable antiretroviral regimes comparing
biochemical and bone mineral density parameters between patients receiving either tenofovir or another nucleoside
reverse transcriptase inhibitor.
Principal Findings: In the unadjusted analysis, there was no significant difference between the two groups in PTH levels
(tenofovir mean 5.9 pmol/L, 95% confidence intervals 5.0 to 6.8, versus non-tenofovir; 5.9, 4.9 to 6.9; p = 0.98). Patients on
tenofovir had significantly reduced urinary calcium excretion (median 3.01 mmol/24 hours) compared to non-tenofovir
users (4.56; p,0.0001). Stratification of the analysis by age and ethnicity revealed that non-white men but not women, on
tenofovir had higher PTH levels than non-white men not on tenofovir (mean difference 3.1 pmol/L, 95% CI 5.3 to 0.9;
p = 0.007). Those patients with optimal 25-hydroxyvitamin D (.75 nmol/L) on tenofovir had higher 1,25-dihydroxyvitamin D
[1,25(OH)2D] (median 48 pg/mL versus 31; p = 0.012), fractional excretion of phosphate (median 26.1%, versus 14.6;
p = 0.025) and lower serum phosphate (median 0.79 mmol/L versus 1.02; p = 0.040) than those not taking tenofovir.
Conclusions: The effects of tenofovir on PTH levels were modified by sex and ethnicity in this cohort. Vitamin D status also
modified the effects of tenofovir on serum concentrations of 1,25(OH)2D and phosphate.
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Introduction
Whilst antiretroviral therapy (ART) has transformed the
prognosis of HIV-1 infection, metabolic consequences such as
osteoporosis, of both infection and its therapy, have become more
common. A meta-analysis found that the prevalence of osteopo-
rosis in HIV-infected subjects was over three times higher than in
HIV-uninfected persons. [1] The exact mechanisms are unclear,
but a combination of factors are thought to contribute to
decreased bone mineral density in HIV-infected people including
lifestyle (e.g. diet, exercise, smoking and alcohol), genetic
influences, as well as direct effects of HIV infection [2] and
administration of antiretrovirals, such as Tenofovir disoproxil
fumarate (TDF) [1,3,4], protease inhibitors (PIs) [1] and zidovu-
dine. [5] Administration of TDF has also been associated with
renal phosphate wasting, [6] osteomalacia [7,8] and more
recently, increased parathyroid hormone (PTH) levels [9–11].
The mechanism behind the potential alteration of calcium and
phosphate homeostasis by TDF is not well understood. Addition-
ally, it remains unclear whether renal phosphate wasting is related
to either reduced bone mineral density and/or hyperparathyroid-
ism in patients receiving TDF.
The aim of this study therefore was to examine the effect of
tenofovir on PTH, calcium and phosphate homeostasis, vitamin D
metabolism and bone mineral density by comparing patients
receiving TDF with patients not receiving TDF. Furthermore, we
aimed to investigate whether these effects are modified by
ethnicity, age and sex.
Methods
Design
We conducted a prospective cohort study.
Participants
Adults (aged .18 years) with HIV-1 infection attending a large
UK outpatient clinic. Patients were recruited between February
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and September 2010 if they had received a non-nucleoside reverse
transcriptase inhibitor (NNRTI)-based antiretroviral regimen
(either with TDF or a nucleoside reverse transcriptase inhibitor
(NRTI)) for greater than 12 months. Patients were excluded if they
had significant renal, hepatic or thyroid dysfunction; concurrent
major systemic illness (including malignancy and granulomatous
infections); metabolic bone disease; were prescribed protease
inhibitors, or were taking vitamin D supplements .400 IU/day
during the preceding 4 months.
Investigations Taken
Patients who gave written informed consent to participate were
given a 24 hour urine collection bottle, had blood drawn, had
weight and height measured using standardised techniques for
calculation of body mass index (BMI), and completed question-
naires to determine exercise habits, dietary calcium intake [12],
dietary vitamin D, demographics, sun exposure [13] and other
lifestyle factors. Reference Nutrient Intakes (RNI) for calcium are
defined as 700 mg/day for both adult men and women [14],
therefore patients’ calcium intakes were categorized into ‘‘Meeting
the RNI’’ or ‘‘Not Meeting the RNI’’. Body composition and bone
mineral density (BMD) of the lumbar spine and femurs were
measured using a Lunar Prodigy dual energy x-ray absorptiometer
(DXA) scanner (GE Healthcare, Madison, WI). The season in
which the blood sample was obtained was classified as summer
(June through August) and ‘other’ for all other months [13].
Laboratory Methods
Serum 25-hydroxyvitamin D [25(OH)D] concentration (refer-
ence range; ,50 nmol/L indicates deficiency; 50–75 nmol/L
insufficiency; .75 nmol/L optimal) was determined by liquid
chromatography-tandem mass spectrometry (LC-MS/MS [15]).
Serum 1,25-dihydroxyvitamin D concentration (normal range,
20–50 pg/mL) was determined by radioimmunoassay following
separation by high performance liquid chromatography (HPLC) as
described in detail elsewhere [16]. Serum parathyroid hormone
(PTH) concentration was determined by automated immunoassay
on the Abbott Architect clinical chemistry analyser (in vitro
chemiluminescent microparticle immunoassay, normal range,
1.1–6.8 pmol/L); bone specific alkaline phosphatase (BAP) con-
centration was determined by an enzyme-linked immunosorbent
assay (ELISA) (Alkphase -BTM; Quidel) (normal range, 15–41 u/L
for males; 11–31 u/L for females). C-terminal Fibroblast growth
factor-23 (FGF-23) concentration was also determined by a 2nd
generation ELISA (Immunotopics, San Clemente, CA, USA)
(normal range ,100 RU/mL) (analysed at the Royal Liverpool
Hospital).
Urine measurements were determined for calcium (normal
range, 2.50–7.50 mmol/24 hours), phosphate, urea and creatinine
by automated Abbott Architect clinical chemistry analyser, and
type 1 collagen N-terminal telopeptide Xlinks (NTX) was assayed
by a competitive-inhibition ELISA (OsteomarkTM; Ostex Inter-
national) (normal range, 1–51 BCE nmol/mmolCreatinine for
males; 5–65 for pre-menopausal women; 5–131 post-menopausal
women). The fractional excretion of phosphate and calcium were
calculated (urine phosphate or calcium6 serum creatinine/serum
phosphate or calcium6 urine creatinine) *100 for those patients
who provided a urine and serum sample on the same day.
Ethics
The study received ethical approval from the Charing Cross
Research Ethics Committee (REC reference number: 09/H0711/
89). All subjects provided written, informed consent.
Statistical Methods
Chi Square, Fisher’s exact, Mann-Whitney and t-tests were used
to assess between-group differences. We used single and multiple
linear regression models for analysing predictors of PTH levels
which have been shown in previous studies to influence PTH,
including the following parameters: serum 25-hydroxyvitamin D
concentration, season, ethnicity, sex, age, dietary calcium intake,
TDF versus other NRTIs, NNRTI use (efavirenz (EFV) versus
nevirapine (NVP)) and total body fat percentage (as determined by
DXA). All variables with a p-value of ,0.10 from the univariate
analysis, in addition to age, NNRTI and TDF use, were entered
into the multivariate model in a forward stepwise fashion using the
Univariate General Linear Model. As the standard errors and
confidence intervals for the model were all within an acceptable
range, we ruled out multicollinearity. For ethnicity, two groups
were considered: white and non-white due to smaller numbers of
participants who identified as an ethnicity other than white. In the
group of women, there were only non-white women, therefore the
comparison of white vs. non-white was only possible within males.
The study aimed to recruit 56 participants, with 28 subjects in
each study group. Assuming a significance level of 0.05, this was
sufficient to detect a 2.5 pg/ml difference in PTH with a standard
deviation of 3.3 [9]. All analyses were done using PASW Statistics
18 (SPSS, IBM, Somers, NY).
Results
Twenty-eight patients receiving TDF and 28 receiving another
NRTI (24 receiving abacavir (ABC), 3 receiving zidovudine (AZT)
and 1 receiving didanosine (ddI) participated in this study. Table 1
describes the demographic and other HIV and ART-related
characteristics of the cohort, and differences between the two
groups. The two groups were well matched for age, sex, ethnicity
and BMI, but more people on a non-TDF containing regime were
taking NVP (85.7% of non-TDF group versus 50.0% of TDF
group) and had biochemical analysis done during the summer
months (85.2% of non-TDF group versus 35.7% of TDF group).
In addition, patients had been receiving non-TDF containing
regimes for longer (median 46 months) than those receiving TDF
(median 35 months). Five patients in the NRTI group and 11 in
the TDF group had osteoporosis or osteopenia of the lumbar spine
or hips (p = 0.09), (see Table 1). Table 2 describes the biochemical
characteristics and differences between the two groups. Patients
receiving TDF were more likely to have lower overall fractional
excretion of calcium (median 0.63%, IQR 0.44 to 1.01) than
patients not taking TDF (1.21%, 0.96 to 1.38) (p = 0.004). No
significant difference in PTH (pmol/L) levels was found between
those taking TDF versus non-TDF (5.9, 95% Confidence Interval
4.9 to 6.9 versus 5.9, 95% CI 5.0 to 6.8; p = 0.98) nor in the
proportion of patients with high PTH (25% versus 30%, p= 0.70)
(see Table 2). Table S1 further describes the biochemical and
medical characteristics of non-white males on TDF and other
NRTIs.
Having compared PTH and other parameters between the two
groups of antiretroviral regimes, we then examined correlates of
PTH in all study participants. Factors significantly associated with
higher PTH levels were lower 25-hydroxyvitamin D, female sex,
non-white ethnicity, lower urinary excretion of calcium, lower
urinary excretion of phosphate, lower dietary intake of calcium,
percentage lean body mass, percentage total body fat, reported sun
exposure, serum calcium, and 1,25(OH)2D:25(OH)D ratio (see
Table S2). Reported sun exposure (being outdoors in daylight,15
minutes, 15–29 minutes, 30–59 minutes, 1–2 hours, 3–4 hours or
.4 hours daily) was a stronger predictor of 25(OH)D (B coefficient
Vitamin D Metabolism and Tenofovir
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8.8; p,0.0001) and PTH (B coefficient 20.5; p = 0.013) than was
season alone (B coefficient 16.9; p = 0.02 and B coefficient 20.8;
p = 0.24 respectively).
Multiple linear regression analysis of determinants of PTH
revealed significant interactions between ethnicity, sex and
tenofovir use, after adjusting for age (see Table 3). Higher PTH
levels were significantly associated with older age and non-white
ethnicity. For the interacting effects found, males on TDF had
higher PTH levels than males on other NRTIs, and non-white
males on TDF had higher PTH levels than both non-white and
white males on other NRTIs, and white males on TDF. TDF use
alone was not significantly associated with PTH levels, nor was
sex.
As vitamin D (25(OH)D) status has shown to have different
effects on PTH and calcium metabolism in patients on tenofovir in
previous studies, we then explored these differences in our cohort.
In patients with optimal 25(OH)D levels, those on TDF had higher
serum 1,25(OH)2D concentration (median 53 pg/mL, IQR 41–61
versus 31, 26–36; p= 0.008, figure 1), fractional excretion of
phosphate (median 29.8%, IQR 20.3–31.9 versus 15.6, 7.8–16.6;
p = 0.05) and lower serum phosphate (median 0.77 mmol/L, IQR
0.71–1.02 versus 1.06, 1.02–1.11; p = 0. 026) than those on other
NRTIs, however, there was no difference in fractional excretion of
calcium (median 1.06%, IQR 0.60–1.39 versus 1.16%, 1.05–1.87;
p = 0.61) or FGF-23 levels. These differences were not seen in
those patients who were vitamin D deficient or insufficient,
however, in those with vitamin D insufficiency (#75 nmol/L),
those on TDF had significantly lower fractional excretion of
calcium (0.56%, IQR 0.42–0.73 versus 1.17%, 0.81–1.38;
p = 0.002).
Discussion
We have carried out a detailed and comprehensive study of
bone, calcium and vitamin D metabolism in relation to TDF,
which has added to our understanding of the effect on TDF on
calcium and vitamin D metabolism. We found that those on TDF
had significantly reduced urinary calcium excretion and that
vitamin D status modified the effect of TDF on markers of calcium
and phosphate metabolism. Patients on TDF had higher levels of
PTH when corrected for other factors, but the effect was only seen
in men who were not of white ethnicity. This is partially consistent
with other observational studies where TDF has been associated
with increased PTH levels [9–11,17].
The physiological response to deficiency of either vitamin D or
calcium is to stimulate PTH secretion. This in turn stimulates the
kidneys to produce 1,25(OH)2D, enhances tubular reabsorption of
calcium (thereby decreasing urinary calcium excretion) and also
activates osteoblasts, leading to an increase in bone alkaline
phosphatase activity [18].
In our study, patients on TDF with optimal 25(OH)D levels
(.75 nmol/L), had higher 1,25(OH)2D levels, a higher fractional
excretion of phosphate and lower serum phosphate levels than on
other NRTIs. These differences were not seen in the presence of
Table 1. Demographic and HIV-related characteristics of the study cohort.
Tenofovir Other NRTIs P-value
N=28 N=28
Male Sex, n (%) 23 (82.1) 20 (71.4) 0.34
Ethnicity: white, n (%) 18 (64.3) 16 (57.1) 0.76
Black, n (%) 7 (25.0) 8 (28.6)
Other, n (%) 3 (10.7) 4 (14.3)
White males, n 18 16
Black males, n 3 1
Other ethnicity males, n 2 3
Age, years 46 (69) 44 (69) 0.50
Months since HIV diagnosis 130 (681) 145 (664) 0.45
CD4 count/mm3 583 (6186) 687 (6235) 0.07
eGFR (MDRD formula, mL/min/1.73 m2) (range) 92 (76–112) 94 (69–118) 0.58
Months on NRTI{ 35 (24–57) 46 (42–68) 0.013*
Nevirapine, n (%) 14 (50.0) 24 (85.7) 0.004*
Efavirenz, n(%) 14 (50.0) 4 (14.3)
Season (summer), n (%) 10 (35.7) 20 (71.4) 0.004*
Outside in daylight hours ,30 min/day, n (%) 10 (35.7) 6 (21.4) 0.17
.3 hours/day, n(%) 9 (32.1) 6 (21.4)
History of corticosteroid use, n (%) 5 (20.0) 5 (22.7) 0.82
Current smoker, n (%) 6 (21.4) 2 (7.1) 0.13
Little to no exercise, n (%) 18 (64.3) 13 (46.4) 0.18
BMI .25 kg/m2, n (%) 18 (64.3) 17 (60.7) 0.60
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, modified diet in renal disease formula; NRTIs, nucleoside reverse transcriptase inhibitor; BMI, body
mass index.
Mean (6SD) unless otherwise stated, {median (IQR).
P –values are between group differences.
doi:10.1371/journal.pone.0044845.t001
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vitamin D deficiency. This suggests that the increased 1 a-
hydroxylation rates and tubular phosphate losses, which drive
calcium preservation and possibly altered bone metabolism
commonly seen in patients on TDF, is dependent on vitamin D
status. Previous studies have had conflicting findings, although it is
difficult to directly compare these due to the different methodol-
ogies and laboratory parameters used. Our study supports the
findings of a prospective Swiss cohort of mainly white men which
found that patients on TDF had higher 1 a-hydroxylation rates
compared to those on other ART only in those patients with
optimal 25(OH)D levels [19]. Others [10], [11] have reported that
TDF was associated with increased PTH levels in those who were
vitamin D deficient and no differences in PTH levels in those who
were vitamin D sufficient. There are several potential explanations
for the alteration we have seen. Several studies have reported
increased renal losses of phosphate in those on TDF. This has
been speculated to be because of either tubular damage due to the
accumulation of TDF within tubular epithelial cells [20] or a
resetting of the renal phosphate threshold [21]. Regardless of the
reason behind increased hyperphosphaturia, this may feedback to
the complex PTH/1,25(OH)2D/calcium pathway. The normal
physiological response to vitamin D deficiency is an increase in
PTH stimulation and a subsequent reduction in renal phosphate
reabsorption. The urinary phosphate losses seen in those on TDF
therefore, may be masked by vitamin D deficiency and only
become apparent in the setting of optimal vitamin D status when
they are evidently ‘unphysiological’. Furthermore, several case
reports of tenofovir-associated Fanconi syndrome have reported
that the majority of these cases had normal 25(OH)D and PTH
levels [22,23], further supporting this theory. Due to the small
numbers in our study, we were unable to further explore this, and
as there have also been conflicting findings in the literature, a
larger longitudinal study would help to further explain the effects
of vitamin D status on calcium and phosphate metabolism in those
on TDF.
The emphasis of this study was on the detailed exploration of
the metabolic consequences of TDF. In particular, several
variables have not been well examined in adults on antiretroviral
therapy, including FGF-23, personal UV exposure and calcium
metabolism.
FGF-23 is the most extensively studied phosphatonin which is
involved in phosphate regulation [24], however the effect that
Table 2. Vitamin D-related biochemical and lifestyle characteristics.
Tenofovir NRTI P-value
Vitamin D deficient, n (%) 14 (52) 13 (48) 0.759
Vitamin D insufficient, n (%) 5 (18) 10 (37)
Optimal vitamin D, n (%) 8 (30) 4 (15)
High PTH, n (%) 7 (25) 8 (30) 0.70
Osteoporosis or osteopaenia, n(%) 11 (39) 5 (19) 0.09
Meeting RNI for calcium, n (%) 7 (26) 6 (21) 0.69
Estimated protein intake, g/kg/d{ 1.11 (0.93–1.23) 1.14 (1.01–1.45) 0.30
Estimated calcium intake, mg/d{ 489 (318–648) 419 (234–746) 0.51
Alkaline phosphatase, u/L 93 (627) 79 (625) 0.04
Serum phosphate, mmol/L 0.95 (60.18) 0.97 (60.13) 0.66
Serum adjusted calcium, mmol/L 2.34 (60.08) 2.34 (60.08) 0.94
Serum 25(OH)D concentration, nmol/L 53 (630) 49 (623) 0.59
Serum 1,25(OH)2D concentration, pg/mL
{ 44 (36–50) 38 (32–42) 0.08
Serum PTH concentration, pmol/L 5.9 (62.4) 5.9 (62.5) 0.98
Bone specific ALP, u/L 35 (613) 30 (610) 0.13
NTX, BCE nmol/mmol Creatinine{ 38 (30–45) 34 (26–41) 0.35
FGF-23, RU/ml{ 21 (15–37) 25 (20–33) 0.48
Urinary calcium, mmol/24 h{ 3.01 (2.15–3.87) 4.58 (3.85–6.18) ,0.0001
Fractional excretion of calcium, %{ 0.63 (0.44–1.01) 1.17 (0.96–1.38) 0.004
Urinary phosphate, mmol/24 h{ 25.44 (21.97–37.77) 28.25 (21.35–38.30) 0.60
Abbreviations: PTH, parathyroid hormone; RNI, reference nutrient intake; NTX, type 1 collage N-terminal telopeptide Xlinks; FGF-23, fibroblast growth factor 23.
Vitamin D deficient (,50 nmol/L), Vitamin D insufficient (50–75 nmol/L), Optimal vitamin D (.75 nmol/L).
Mean (6SD) unless otherwise stated, {Median (IQR).
doi:10.1371/journal.pone.0044845.t002
Table 3. Multivariate linear regression analysis of serum PTH
levels.
Variable Coefficient B (95% CI) SE P-value
ART 4.06 (0.86 to 7.26) 1.60 0.69
Sex 1.13 (21.08 to 3.35) 1.10 0.30
Ethnicity 3.54 (1.90 to 5.17) 0.81 0.003
Age 0.08 (0.03 to 0.13) 0.03 0.004
ART*Sex 23.81 (26.81 to 20.81) 1.49 0.014**
ART*Ethnicity 23.29 (25.75 to 20.84) 1.22 0.01**
**p-value for interaction effect.
R2 = 0.515 (Adjusted R2 = 0.452).
Abbreviations: ART, antiretroviral therapy.
doi:10.1371/journal.pone.0044845.t003
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TDF use may have on its stimulation or catabolism has not been
reported. Our study demonstrated that FGF-23 levels did not
differ between TDF and non-TDF containing ART, however two
patients receiving TDF and NVP were found to have extremely
high FGF-23 levels (.300 RU/mL). Additionally, we did not see a
difference in FGF-23 levels in those with optimal vitamin D status
and increased 1,25(OH)2D. Bech et al [21] recently reported that
when comparing two groups of patients on TDF with and without
hypophosphataemia, no differences were seen in FGF-23 levels
between the two groups, questioning the role of FGF-23 in altered
phosphate metabolism sometimes seen in HIV-infected patients on
TDF. We used a C-terminal assay to measure FGF-23, which was
also used by Bech et al, that measures both the intact and
biologically inactive portions of FGF-23. Burnett et al [25]
compared the differences between the C-terminal and intact
assays. The intact FGF-23 assay showed the effects of the
associations between FGF-23 and serum phosphate, fractional
excretion of phosphate and 1,25(OH)2D more clearly than the C-
terminal assay. Therefore evaluating intact FGF-23 in patients on
TDF would be worthwhile in future studies. Abnormally elevated
FGF-23 levels are seen in several pathological conditions and are
associated with hypophosphataemia, low 1,25(OH)2D, urinary
phosphate wasting and osteomalacia. One study in Gambian
children with rickets found extremely high FGF-23 in these
patients along with high 1,25(OH)2D and low dietary calcium
[26]. The two women in our study with high FGF-23 also had
high 1,25(OH)2D levels and low dietary calcium intakes, however
they did not have phosphaturia and had normal bone mineral
density which is unexpected and appears to signify an abnormality
in phosphate metabolism in these individuals.
In this study, reported time outdoors as a surrogate of personal
UV exposure was a stronger determinant of both 25(OH)D and
PTH than season alone. Photophobia, photosensitivity, immobil-
ity, depression and sun avoidance due to the perceived increased
risk of skin cancer may be potential factors altering sun exposure
practices in people living with HIV. We are the first to describe a
lower 24 hour urinary calcium excretion and fractional excretion
of calcium in patients on TDF with eight patients on TDF with
urinary calcium excretion lower than the reference range. No
differences in urinary calcium excretion were found in a
longitudinal study comparing patients starting on TDF versus
ABC [10]. These patients were only followed until week 48, and
our cohort comprised of patients who had been on ART for
greater than 52 weeks, therefore it is possible that the cumulative
effect of TDF use may decrease calcium excretion. Higher
1,25(OH)2D levels in patients on TDF were found in this study
and in others [19], therefore the finding of reduced calcium
excretion would be in keeping with the physiological response to
an increased 1,25(OH)2D level, but it appears to be unrelated to
the increased fractional excretion of phosphate also found in those
on TDF. As we used LC-MS/MS to determine 25(OH)D, which
can differentiate between 25(OH)D and other metabolites,
Figure 1. 1,25(OH)2 vitamin D differences according to 25(OH)vitamin D and ART regime.
doi:10.1371/journal.pone.0044845.g001
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including 24,25(OH)2D, which may be altered in those on ART,
we can rule out possible cross-reactivity with 24,25(OH)2D in our
25(OH)D measurement. The clinical significance of this finding
cannot be determined from a cross-sectional analysis.
Many of our participants had very low intakes of dietary
calcium as only 24% met the RNI for calcium (700 mg/day). In
the general population, the mean intake of dietary calcium is well
above the RNI for both men and women [27]. There are often
ethnic differences in calcium intake, especially historical intake,
and it has been reported that some people of African origin have
higher PTH levels which may be due to their low dietary calcium
intake [28]. In our study, those of African origin had significantly
lower intakes of dietary calcium (data not shown). Dietary calcium
deficiency has been associated with increased parathyroid
hormone secretion especially in the presence of 25(OH)D
deficiency [29]. However, many studies evaluating PTH levels in
patients with HIV infection have not examined dietary influences
on PTH levels. Our study also found that in simple linear
regression, lower dietary calcium intakes were associated with
higher PTH levels. Therefore the interplay between dietary
calcium intake and ethnicity should be considered, especially in
ethnically diverse cohorts.
Limitations in this study include the small numbers in each
group of patients, and the absence of white women which limited
the ability to detect differences in the ethnicity subanalyses. In
addition, the length of time taking NRTIs, the NNRTI used and
season of biochemical measurement was significantly different
between the groups. This was primarily due to the increase in
prescribing of TDF after its approval by the European Medicines
Agency in 2002. However, these variables were not predictors of
PTH in either the simple linear or multivariate analyses.
Larger, multi-ethnic studies are needed to confirm our findings
about the interaction between TDF use and non-white males.
Additionally, future studies should examine prospectively the effect
of vitamin D status and vitamin D supplementation on calcium
and phosphate metabolism, and the contributing effect of different
antiretroviral regimes, to try and clarify these relationships.
Conclusions
The effect of TDF on PTH levels seems to be dependent on sex
and ethnicity. This study was not able to demonstrate a link
between hyperparathyroidism and altered bone metabolism nor
renal tubular dysfunction frequently seen in patients on TDF.
Vitamin D deficiency appeared to be ‘overriding’ the effect of
TDF on 1 a-hydroxylation of vitamin D. Urinary calcium
excretion was significantly lower in all patients on TDF. Future
studies should confirm this as there have been inconsistent findings
from other studies.
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